FindTrial
Sign In

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

BIOLOGICAL3 trials

Sponsors

City of Hope Medical Center

Conditions

B Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Mantle Cell LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Mantle Cell Lymphoma

Phase 1

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
Active, not recruitingNCT02146924
City of Hope Medical CenterB Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Start: 2014-10-16End: 2027-06-17Updated: 2026-08-05
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
SuspendedNCT06447987
City of Hope Medical CenterRecurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Start: 2024-11-06End: 2026-12-05Target: 24Updated: 2026-06-05

Phase 2

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
RecruitingNCT04484012
City of Hope Medical CenterRecurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Start: 2020-12-31End: 2026-09-02Target: 36Updated: 2025-11-26

Related Papers

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission
Blood Advances2026-06-24
Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies
Blood Advances2024-06-172 citations
CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)
Blood2023-11-023 citations
Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
Blood2022-11-152 citations
The Vulnerability of Patients With Leukemia at Risk for Financial Toxicity
Oncology Times2019-05-13
Adult Patients with ALL Treated with CD62L+ T Naïve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile
Blood2018-11-2911 citations